Van Hauwermeiren et al. also supported the hypothesis of selectively inhibiting TNFR1 to achieve better therapeutic outcomes in MS and other diseases where TNFR2 blockade may be harmful [33]. The gene discussed is TNFRSF1A; the disease is myeloid sarcoma.